HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
S7475 NU9056 NU9056 is a potent and selective inhibitor of Tip60 (KAT5) histone acetyltransferase with an IC50 value of 2 µM. NU9056 demonstrates over 16-fold selectivity for Tip60 compared to PCAF, p300, and GCN5 and effectively induces apoptosis in prostate cancer cells. Oct 24 2024
S9813 dTAG-13 dTAG-13(FKBP12 PROTAC dTAG-13) is an ortho-substituted, heterobifunctional selective degrader of FKBP12F36V that effectively engage FKBP12F36V and CRBN leading to rapid and selective CRBN-mediated degradation of FKBP12F36V.It can useful for target validation in the context of drug discovery. Oct 23 2024
E4650 Ladarixin Ladarixin(DF 2156A free base) is a small molecule, orally available, allosteric and non-competitive antagonist of dual CXCR1 and CXCR2. It is able to reduce the acute and chronic neutrophilic influx, and can be used in research of Asthma, Idiopathic Pulmonary Fibrosis, Influenza-A infection and COPD, cutaneous and uveal melanoma conditions. Oct 23 2024
E4697 RGT-018 RGT-018, is a potent and selective inhibitor of SOS1. It blocks the interaction of KRAS:SOS1 with an IC50 of 8 nM and inhibited KRAS signaling and the proliferation of KRAS-driven cancer cells. It may exhibit potent anticancer activity against NSCLC, colorectal cancer, and pancreatic cancer. Oct 23 2024
E4980 Verapamil Verapamil(Iproveratril,Dilacoran), is a phenylalkylamine derivative which is an antagonist of calcium influx and also an inhibitor P-gp and CYP3A4. It exhibits potency in treatment for angina, cardiac arrhythmias, cardiomyopathies and hypertension. Oct 23 2024
E4969 Avatrombopag hydrochloride Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP). Oct 23 2024
E1881 NVS-STG2 NVS-STG2(HY-157214) is a potent, allosteric small molecule agonist of STING. It binds at the transmembrane domain (TMD) interface of STING, thereby acting as a molecular glue to promote STING oligomerization and contribute to its activation. It may be used in research of STING-related autoimmune diseases. Oct 23 2024
E4643 BIIB129 BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS). Oct 23 2024
E4714 Xanomeline Xanomeline(LY-246708) is a selective agonist of muscarinic type 1(M(1) receptor and muscarinic type 4 receptor(M(4). It increases neuronal excitability and inhibits behaviors induced by D-amphetamine and (-)-apomorphine. Oct 23 2024
E1600 AMG-193 AMG-193 is an orally active and MTA-cooperative inhibitor of PRMT5 with potent biochemical and cellular activity. AMG-193, in combination with MTA, selectively targets and inhibits the growth of MTAP-deficient tumor cells by suppressing PRMT5, with an IC50 of 0.107 μM, while sparing normal cells that possess wild-type MTAP. AMG-193 also exhibits antitumor activity. Oct 22 2024
E4873 Mebhydroline Mebhydroline acts as a selective antagonist of farnesoid X receptor (FXR). Mebhydrolin improves blood glucose balance in in vivo mice models by inhibiting hepatic gluconeogenesis through the FXR/miR-22-3p/PI3K/AKT/FoxO1 pathway and enhancing glycogen synthesis. It also acts as a specific antagonist of histamine H1 receptor. It has potential for its use in the treatment of Type 2 diabetes mellitus (T2DM). Oct 22 2024
E4987 (S)-Flurbiprofen (S)-Flurbiprofen (Esflurbiprofen), an active enantiomer of Flurbiprofen, acts as an inhibitor of cyclooxygenase (COX-2) with an IC50 value of 0.48 μM, respectively. It also helps in the significant reduction of the inflammatory mediator-induced CGRP release. Oct 22 2024
E4881 Ifenprodil Ifenprodil(Dilvax, RC 61-91) is a potent antagonist of N-methyl-D-aspartate (NMDA) receptor that selectively inhibits receptors containing the NR2B subunit. It exhibits potential for its use in the treatment of various neurological diseases. Oct 22 2024
E4971 Oclacitinib Oclacitinib(PF-03394197), an inhibitor of JAK is highly potent at inhibiting JAK1 with an IC50 value of 10 nM, respectively. Oclacitinib is highly potent against the JAK1 enzyme, displaying a 1.8-fold selectivity for JAK1 vs. JAK2 and a 9.9-fold selectivity toward JAK1 vs. JAK3. Oct 22 2024
E4938 Diphenylpyraline Diphenylpyraline(Allergen, Difenilpiralina; 4-Diphenylmethoxy-1-methylpiperidine), also known as 4-Diphenylmethoxy-1-methylpiperidine, is a first-generation antihistamine that acts as an antagonist of the histamine H1 receptor. It provides therapeutic antiallergic effects and has the potential to treat cocaine addiction. Oct 17 2024
E4814 Teneligliptin Hydrobromide Hydrate Teneligliptin Hydrobromide Hydrate(MP-513 hydrobromide hydrate) is a potent, competitive, and long-lasting inhibitor of DPP-4. It competitively inhibited rhDPP-4, human plasma, and rat plasma with IC50 values of 0.889, 1.75, and 1.35 nM respectively. It suppresses high glucose-mediated mitochondrial dysfunction and can be used for treatment of type 2 diabetes. Oct 17 2024
E1982 SOP1812 SOP1812( QN-302), is a tetra-substituted naphthalene diimide (ND) derivative and selective inhibitor of G-quadruplex (G4) transcription. It shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. It binds to G-quadruplex DNA in cancer gene promoters region and shows strong anti-proliferative and anti-tumor activity in pancreatic cancer models. Oct 17 2024
E4709 MS-L6 MS-L6(Agn-PC-0N3ahi, NSC34338) is a potent inhibitor of OXPHOS, targeting electron transport chain complexes I (ETC-I), combining inhibition of NADH oxidation and uncoupling effect, on the respiratory chain. It exhibits potent antitumor efficacy. Oct 17 2024
E4628 BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure. Oct 15 2024
E4703 Culmerciclib Culmerciclib (TQB3616) is a potent inhibitor of cyclin dependent kinase (CDK)4/6 and exhibits highly effective antineoplastic activity. TQB3616 exhibits significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer when combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy. Oct 15 2024